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Abstract 7 
Erythropoiesis is one of the most demanding processes in the body, with over two million red blood 8 
cells produced every second. Multiple hereditary and acquired red blood cell disorders arise from 9 
this complex system, with existing treatments effective in managing some of these conditions but 10 
few offering a long-term cure. Finding new treatments relies on the full understanding of the cellular 11 
and molecular interactions associated with the production and maturation of red blood cells, which 12 
takes place within the erythroblastic island niche. The elucidation of processes associated within the 13 
erythroblastic island niche in health and during stress erythropoiesis has relied on in vivo modelling 14 
in mice, with complexities dissected using simple in vitro systems. Recent progress using state of the 15 
art stem cell technology and gene editing has enabled a more detailed study of the human niche.  16 
Here, we review these different models and describe how they have been used to identify and 17 
characterise the cellular and molecular pathways associated with red blood cell production and 18 
maturation. We speculate that these systems could be applied to modelling red blood cell diseases 19 
and finding new druggable targets, which would prove especially useful for patients resistant to 20 
existing treatments. These models could also aid in research into the manufacturing of red blood 21 
cells in vitro to replace donor blood transfusions, which is the most common treatment of blood 22 
disorders. 23 
  24 
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1. Introduction 1 
The erythroblastic island, first visualised by Marcel Bessis in 1958, is the site of erythropoiesis in 2 
mammals (1). Erythroblastic islands are predominately situated in the bone marrow during steady-3 
state erythropoiesis, but expand in the fetal liver and adult spleen during stress erythropoiesis when 4 
there is a rapid production of erythrocytes in response to inflammation and anemia (1-4). The island 5 
consists of a central macrophage (erythroblastic island [EBI] macrophage), surrounded by developing 6 
erythroblasts, which was hypothesised to supply ferritin to the developing erythroblasts for 7 
hemoglobin synthesis (5, 6). Additional functions of the central macrophage have since been 8 
elucidated, confirming its role as a supportive ‘nurse’ cell during erythropoiesis. EBI macrophages 9 
support erythroblast differentiation through cell-cell contact and secreted supportive factors, 10 
promoting the maturation and enucleation of erythroid cells and the phagocytosis of their expelled 11 
nuclei (7-10).   12 
While there have been extensive studies into the hematopoietic stem cell (HSC) bone marrow niche 13 
microenvironment, the erythroblastic island niche (EBI niche) has been the focus of a relatively small 14 
number of research groups (11-13).  In contrast to the vast array of cell types implicated in the HSC 15 
niche, the EBI niche appears to be relatively simple with no other cell type being implicated to work 16 
in concert with EBI macrophages (14).  This offers the EBI as a unique and streamlined niche to study 17 
red blood cell (RBC) development in health and disease and the development of model systems is 18 
relatively straightforward.  19 
Anemia represents the most prevalent RBC disorder and is crudely defined as a condition in patients 20 
who lack adequate numbers of healthy RBCs and diagnosed by a low blood hemoglobin (Hb) 21 
concentration (15).  Anemia affects approximately 1.62 billion people worldwide, accounting for 22 
8.8% of the total worldwide disease burden (16, 17). RBC disorders represent a broad spectrum of 23 
conditions, spanning inherited disorders such as thalassemia and sickle cell anemia, to acquired 24 
disorders such as polycythemia vera and paroxysmal nocturnal hemoglobinuria (PNH), with mild to 25 
fatal clinical outcomes (18-22).  26 
Current treatments for RBC disorders include blood transfusions and iron chelation therapy to 27 
counteract iron accumulation in patients requiring repeated transfusion, or iron supplements for 28 
iron-deficiency anemia (23, 24). Several drugs that stimulate erythropoiesis have been approved, 29 
such as erythropoietin (EPO) that is used routinely to treat anemias associated with chronic kidney 30 
disease and cancer (25-27). Rarer RBC disorders, such as PNH, have fewer effective treatment 31 
options and these are often prohibitively expensive. Eculizumab, for example, is a monoclonal 32 
antibody against terminal complement protein C5 that is used to reduce hemolysis and stabilise 33 
hemoglobin levels. Not only is it widely reported as one of the world’s most expensive drugs at a 34 
cost of around $400,000 per year of treatment, but only 20% of patients reach normal hemoglobin 35 
values and 40% remain anemic (28, 29). Some RBC disorders, including PNH and acquired aplastic 36 
anemia, can be effectively cured by bone marrow transplantation (30, 31) but this procedure is 37 
associated with significant morbidity and mortality rates due to the requirement for preconditioning 38 
which ablates the haematopoiesis of the host (31, 32). There is a clear clinical need for the 39 
development of new therapies to treat RBC disorders.  40 
A full understanding of the cellular and molecular pathways involved in the EBI niche and how these 41 
contribute to stress erythropoiesis and disease would allow for the development of new therapies to 42 
treat RBC disorders. Early models of the EBI niche provided insights into its structure and 43 
organisation, later followed by more sophisticated genetic models that demonstrated the roles of 44 
individual genes in the niche in both animal models and humans.  Here, we review the in vivo and in 45 
 3 
vitro models that have been used to study the EBI niche. We discuss the advantages and 1 
disadvantages of each (Table 1) and summarise some of the key advances that have been made 2 
using these models in our understanding of steady-state, stress and disease erythropoiesis (Figure 3 
1). 4 
2. Erythropoiesis and the EBI 5 
In the first stage of RBC production, HSCs sequentially differentiate to common myeloid progenitor, 6 
megakaryocyte-erythroid progenitor, burst-forming unit-erythroid (BFU-E), and colony-forming unit-7 
erythroid (CFU-E) progenitor cells (33-36). In the second stage, CFU-E progenitor cells differentiate 8 
through the morphologically distinct nucleated precursors proerythroblast, basophilic erythroblast, 9 
polychromatic erythroblast and orthochromatic erythroblast (37). As the differentiating erythroid 10 
cells mature nuclear chromatin is condensed and cytoskeletal remodelling occurs in preparation for 11 
nuclear expulsion (38, 39).  12 
The proerythroblast to orthochromatic stages of differentiation occur within the EBI. Macrophage-13 
erythroblast adhesion molecules function to promote erythroblast proliferation and are highly 14 
expressed in proerythroblasts, with expression progressively lost by the orthochromatic erythroblast 15 
stage (40-42). The central macrophage secretes cytokines that promote the enucleation of 16 
erythroblasts, and provides iron for heme synthesis (6, 8, 43, 44). The composition of EBIs varies 17 
slightly across species, with rat EBIs containing consistently around 10 erythroblasts per island 18 
compared to much more variable human EBIs, where 5 to 30 erythroblasts can be found surrounding 19 
the central macrophage (45, 46).  20 
At the final terminal differentiation stage, the nucleus is expelled from the orthochromatic 21 
erythroblast and phagocytosed by the EBI macrophage (47). The resulting reticulocyte expels any 22 
remaining organelles and enters circulation (38). Considerable membrane remodelling then takes 23 
place to generate fully mature, biconcave erythrocytes (48, 49).  24 
3. Modelling the EBI Niche using Animal Models  25 
3.1. Isolation of intact EBIs  26 
Early investigations into the structure and organisation of EBIs involved careful isolation and study of 27 
rodent bone marrow using various types of microscopy (50). The first image of an EBI, obtained by 28 
Bessis in 1958, was achieved by examining bone marrow preparations using phase-contrast 29 
microscopy (1). Light and electron microscopy were later used to construct three-dimensional 30 
reconstructions of rat bone marrow, showing distinct in situ EBIs in which erythroblasts underwent 31 
maturation in close association with macrophages (2). After these initial morphological assessments 32 
of the central mononuclear cells present in EBIs as macrophages, F4/80 antibody staining confirmed 33 
that resident macrophages in mouse bone marrow formed the EBIs (51). Light and electron 34 
microscopy has also been used to demonstrate that EBIs are not spatially restricted within the bone 35 
marrow and their composition is altered depending on their location. For example, EBIs adjacent to 36 
sinusoids are enriched for orthochromatophilic erythroblasts, while nonadjacent EBIs are enriched in 37 
proerythroblasts, suggesting a mechanism in which islands migrate to sinusoids as erythroid 38 
differentiation progresses (52). Although the information gleaned from microscopy studies tends to 39 
present EBIs as static structures, the fact that they migrate indicates that they are actually quite 40 
dynamic and it is likely that the cell-cell interactions change over time.  In tandem with microscopy 41 
studies, isolated EBIs were further characterised via antibody staining (53). EBIs were found to range 42 
from 5-100 cells, and the majority of isolated islands contained at least one F4/80+ central 43 
macrophage (53). Isolation of intact EBIs from different hematopoietic tissues and subsequent 44 
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analysis of known EBI macrophage cell surface markers revealed them to be a heterogeneous 1 
macrophage population (54-56). Mouse and rat EBIs heterogeneously express VCAM-1, F4/80 and 2 
CD169, while CD163 was only expressed by rat macrophages (54). The study of intact EBIs provided 3 
visual data for the composition of islands and is useful for characterising the component phenotypes 4 
of the EBI niche in vivo but it has limitations. It is a static system and cannot be used to dissect the 5 
molecular mechanisms associated with its function (Table 1).  6 
3.2. In vitro reconstitution of EBIs 7 
As well as ex vivo culture of EBIs harvested from rodents, the reconstitution of EBIs in vitro through 8 
the co-culture of erythroblasts and macrophages was first proposed in 1979, and is now a method 9 
widely employed (9, 42, 57-60). Through studies using reconstituted EBIs it was observed that 10 
macrophages support erythroid differentiation through their direct contact with erythroblasts via an 11 
EPO-independent mechanism, with cultured erythroblasts proliferating 3-fold more when in contact 12 
with macrophages (41, 42). 13 
Studies employing reconstituted EBIs have been used to elucidate proteins involved in erythroblast 14 
and macrophage interactions. Erythroblast-macrophage attachments within the EBI niche are 15 
important in promoting erythropoiesis, and the adhesion proteins that facilitate these attachments 16 
are critical for island integrity. One of the first proteins identified to be involved in erythroblast-17 
macrophage attachment was α4β1 integrin on erythroblasts that binds VCAM-1 on macrophages 18 
(55). Blocking monoclonal antibodies against α4β1 integrin and VCAM-1 significantly impaired 19 
erythroblast-macrophage attachment, demonstrating that this interaction is critical for island 20 
integrity (55). Reconstitution of EBIs in vitro has been a powerful model to observe the dynamic 21 
relationship between cell types, but the strategy is limited by culture conditions and does not allow 22 
for investigation of the possible interactions of other cell types in the bone marrow. Furthermore, it 23 
is unclear how this relates to the in vivo situation and how transferable it would be to the human 24 
EBI. (Table 1).  25 
3.3. Macrophage depletion models 26 
3.3.1. Macrophage depletion models in stress erythropoiesis 27 
Macrophage depletion has been a particularly useful model to investigate the role of the 28 
macrophage compartment of the EBI niche in vivo. Macrophages can be depleted by administering 29 
clodronate-encapsulated liposomes which are phagocytosed and induce apoptosis (61-63) or using 30 
the CD169-DTR mouse strain which expresses the human diphtheria toxin receptor (DTR) under the 31 
control of the endogenous Siglec-1 (CD169) promotor (64). Macrophage depletion is relatively easy 32 
to achieve, and can be applied to the different genetic models (Table 1).  33 
Macrophage depletion models have been used to study the contribution of EBI macrophages to 34 
stress erythropoiesis in addition to the contribution of microenvironmental cells, for example splenic 35 
endothelial cells secrete SCF that mediates stress erythropoiesis in response to myeloablation, 36 
bleeding and pregnancy (65). Macrophage depletion has been shown to severely compromise stress 37 
erythropoiesis, impairing recovery from anemia, acute blood loss and myeloablation. In a study in 38 
which macrophages were depleted using clodronate there was a significant reduction in 39 
reticulocytes and erythroid precursors in both the bone marrow (BM) and spleen (62, 63). Depletion 40 
of CD169+ macrophages using the CD169-DTR mouse model impaired recovery from hemolytic 41 
anemia and acute blood loss, and this was associated with a reduced number of EBIs and 42 
erythroblasts in bone marrow (66). In two models of acute RBC reduction, phenylhydrazine induced 43 
anemia and acute blood loss, a delay in hematocrit recovery was observed. There was also a delay in 44 
 5 
the recovery of erythroblast numbers in myeloablation following BM transplant and following 1 
challenge with the myeloablative agent 5-fluorouracil (66). 2 
One hallmark of stress erythropoiesis is the shift from erythropoiesis in the BM to extramedullary 3 
sites such as the liver and spleen, and the generation of stress erythroid progenitors (SEPs)(4, 67-69). 4 
During recovery from anemic stress, CCL2 production recruits monocytes to the spleen, where they 5 
associate with SEPs and differentiate into red pulp macrophages (RPM) creating new EBIs (70). In 6 
steady state conditions RPMs, a population of tissue resident macrophages, contribute to 7 
maintaining erythroid homeostasis by phagocytosing senescent erythrocytes, recycling iron and 8 
degrading heme (71). These RPMs have also been observed to form EBIs following transplantation 9 
and myeloablation (72). Splenic RPMs secrete BMP4 which is essential for the recovery of erythroid 10 
cells following a bone marrow transplant induced model of myeloablation (66). Spleens of CD169+ 11 
macrophage-depleted mice, which had impaired erythroblast recovery, expressed significantly less 12 
BMP4 and reciprocal transplantation studies identified splenic RPM as the source of this BMP4 (66).  13 
3.3.2. Macrophage depletion models in disease 14 
Macrophage depletion models have been used to implicate the macrophage compartment of the EBI 15 
niche in various RBC diseases. In a murine model of polycythemia vera (PCV), a disease in which 16 
there is excessive production of erythroid cells as a result of a point mutation in JAK2 (JAK2V617F), 17 
blood hematocrit was normalised following depletion of CD169+ macrophages (66, 73, 74). Using the 18 
Jak2V617F/+ murine model of PCV, researchers demonstrated that clodronate-mediated macrophage 19 
depletion also normalised RBC numbers (63, 75).  JAK2 is a component of the EpoR signalling 20 
cascade, and the results of these macrophage depletion studies imply that the hyperactive EpoR 21 
signalling caused by the JAK2V617F mutant protein within the macrophage compartment contributes 22 
to the disease phenotype in this model of PCV (74). The fact that the number of macrophages 23 
increase in response to EPO administration in control mice confirms that EpoR signalling is indeed 24 
active in macrophages as well as erythroid cells within the EBI (76) and this is further supported by 25 
the expansion of both erythrocytes and macrophages in mouse models of erythrocytosis (76). 26 
Macrophage depletion also improved the phenotype of a mouse model of β-thalassemia, with mice 27 
treated with clodronate exhibiting increased hemoglobin and RBC numbers (63, 77). Therefore, 28 
macrophages have been demonstrated to influence disease phenotypes by both increasing and 29 
decreasing RBC numbers.  30 
While macrophage depletion has been an effective method to elucidate the role of EBI macrophages 31 
in stress and disease erythropoiesis, having been demonstrated to deplete CD169+ VCAM+ EBI 32 
macrophages, EBI macrophages are not exclusively depleted (Table 1). It is unclear what 33 
contribution, if any, the depletion of other macrophage subsets has on erythropoiesis. Further 34 
studies to isolate and deplete only EBI macrophages are needed to fully elucidate their contribution 35 
to disease.   36 
3.4. Genetically modified mouse models 37 
With the advent of gene editing technology, the role of specific genes in the EBI niche could be 38 
assessed in vivo using genetically modified mice (Table 1). Targeted deletion of genes hypothesised 39 
to have an important role in EBIs was used to strengthen observations made in previous in vitro 40 
studies. For example, antibody inhibition studies in vitro identified that ICAM-4, a member of the 41 
intercellular adhesion molecule family expressed in erythroid cells, binds to α4 β1integrin and αv 42 
integrins (78). The subsequent production of ICAM-4- null mice confirmed that its interaction with 43 
αv integrins on macrophages is involved in maintaining EBI integrity (58). Islands were harvested 44 
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intact from ICAM-4-null mice or reconstituted in vitro and a significant decrease in reconstituted 1 
islands was observed in isolates from ICAM-4 null compared to WT mice, supporting the functional 2 
role of αv integrin in EBI macrophages (58).  3 
Targeted gene inactivation using a gene trapping approach confirmed the in vivo function of Emp 4 
(erythroblast-macrophage protein), which had been previously implicated as an important mediator 5 
of erythroblast-macrophage attachment in vitro (41, 79). Emp null embryos die shortly after birth 6 
and present with an increased number of nucleated, immature erythrocytes in their peripheral 7 
blood (80). The phenotype is especially stark in the fetal liver, where almost no EBIs were observed. 8 
Interestingly, control, wild type macrophages were still able to bind Emp-deficient erythroblasts but 9 
these erythroblasts failed to enucleate. Further insight into macrophage/erythroid interactions via 10 
Emp was gleaned from a macrophage-specific conditional gene deletion of Emp (Maea) that resulted 11 
in severely impaired EBI formation, whereas deletion in the erythroid lineage had no detrimental 12 
effect (81). Together, these studies indicate that Emp regulates the maintenance of macrophages 13 
and that Emp-mediated adhesion to erythroblasts must involve another currently unidentified 14 
receptor on erythroid cells (81).  15 
Gene targeting studies in mice have also addressed the role of EBI macrophages in promoting 16 
enucleation via cell-cell attachments and in its function to phagocytose nuclei extruded from the 17 
erythroblasts. Nuclei are extruded as ‘pyrenocytes’,  small, nucleated cells with a cytoplasmic ring 18 
(9). Pyrenocytes externalise phosphatidylserine providing a signal to macrophages for engulfment 19 
(47). The endonuclease DNaseII (Dnase2) in EBI macrophages destroys the nucleus expelled from 20 
erythroblasts as demonstrated in DNaseII-deficient mice, where undegraded DNA stimulates EBI 21 
macrophages to express IFN-β, therefore inhibiting erythropoiesis (82).  It was particularly 22 
interesting to note that expression of Dnase2a in EBI macrophages is regulated by KLF1 (7, 83), a 23 
transcription factor that was first identified as a master regulator within the erythroid lineage, with 24 
an important role in regulating the later stages of RBC production including globin switching to the 25 
activation of erythroid-specific genes (84-87).  Adding to its critical intrinsic role, an extrinsic role for 26 
KLF1 in the macrophage compartment of the erythroblastic island niche was first implicated using a 27 
KLF1-eGFP reporter mouse strain where GFP was detected in EBI macrophages and genes associated 28 
with island integrity such as VCAM1 expressed at a higher in KLF1-GFP+ macrophages (8, 88, 89). 29 
Stress erythropoiesis has been shown to be particularly sensitive to modifications in the EBI niche, 30 
and mouse genetic models have also been used to assess the role of specific genes in that process 31 
(4). Steady state and stress erythropoiesis are thought to be regulated by different mechanisms with 32 
EBI macrophages being more strongly implicated under stress conditions. Growth-differentiation 33 
factor 15 (Gdf15), for example, is an essential regulator of stress, but not steady-state, 34 
erythropoiesis in both mice and humans (90, 91). Gdf15-/- mice exhibit a reduced expansion of the 35 
splenic stress erythroid niche from monocyte recruitment, resulting in an impaired proliferation of 36 
stress erythroid progenitors (SEPs)(91). It was demonstrated that Gdf15 signalling modulates Hif2α-37 
dependent expression of BMP4 in macrophages through Vhl inhibition, which in turn regulates SEP 38 
proliferation (91).  39 
Characterisation of the Epor-eGFP knockin reporter mouse demonstrated that the majority of EBI 40 
macrophages express the Epo receptor, implying that Epo can act on both macrophages and 41 
erythroid cells (56).  It was recently shown that Epo/Stat signalling in splenic EBI macrophages 42 
represses the Wnt signalling that promotes SEP proliferation so the end result of macrophage Epo 43 
signalling is the differentiation of SEPs into functionally mature RBCs (92). 44 
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Stress erythropoiesis can also be induced during inflammation, where bone marrow hematopoiesis 1 
favours the production of innate immune effector cells at the expense of RBC production (93). 2 
Inflammation induced anemia is common in patients with chronic inflammation, and several pro-3 
inflammatory cytokines, such as TNF-α and IFN-γ, have been shown to inhibit steady-state 4 
erythropoiesis (94-97). A recent study using a mouse model of sterile inflammation, demonstrated 5 
this inhibition is compensated by an increase in stress erythropoiesis.  Signalling through Toll-like 6 
receptors (TLRs) stimulated the phagocytosis of erythrocytes by splenic macrophages, facilitating 7 
heme-dependent expression of the transcription factor SPI-C which in turn promoted the expression 8 
of both Gdf15 and Bmp4 that act to increase the proliferation of SEPs (98).  9 
Could changes in the EBI niche contribute to RBC disorders as well as stress erythropoiesis, and if so, 10 
could modulation of the EBI niche be exploited to treat these RBC conditions? Experimental 11 
evidence in mouse models suggests that modulation of the EBI niche could be effective in treating 12 
RBC disorders. EPO, a hormone widely used to stimulate erythroblast production and maturation, is 13 
not always effective, with many anemic patients unresponsive to treatment (99, 100). Growth 14 
arrest-specific factor 6 (Gas6), a protein secreted by erythroblasts in response to EPO, enhances EPO 15 
signalling directly by activating the Akt survival pathway in erythroblasts, and indirectly by reducing 16 
the release of erythroid-inhibitory factors from macrophages in the EBI niche (101). In a Gas6-/- 17 
mouse model there is an increase in the expression of various cytokines known to inhibit 18 
erythropoiesis, for example IL-10, IL-13, and TNF-α (101). Thus, Gas6 could be a targeted as a 19 
potential therapeutic option that would act on both erythroblasts and EBI macrophages to promote 20 
erythropoiesis.  21 
One major advantage of using genetic models is that, unlike in vitro models of the EBI niche, genetic 22 
models in mice has allowed for the dissection of the role of specific genes in vivo. However, they are 23 
much more expensive and complex than in vitro studies, and still may not accurately reflect the 24 
human system (Table 1).  25 
4. Modelling the Human EBI Niche  26 
The mouse models described have all contributed significantly to our understanding but how closely 27 
this resembles the human EBI niche is unclear. Work so far has focussed on the EBI macrophage, a 28 
key cell type in promoting erythropoiesis, but this has not allowed for the investigation into the 29 
involvement of other cell types (Table 1). Human EBIs can be isolated from bone specimens resected 30 
during surgery, for example ribs during thoracic surgery, or from sectioned bone marrow (45). 31 
Sourcing this tissue however is extremely difficult. Thus, the majority of studies into the human EBI 32 
niche have relied on in vitro modelling, mainly using cells sourced from peripheral blood. Recently, 33 
components of the EBI niche have been derived from either pluripotent stem cells or CD34+ 34 
hematopoietic progenitors and used to further characterise the human EBI niche (8).  35 
4.1. Hematopoietic progenitor cell-derived macrophages 36 
Modelling of the human EBI niche has been possible using CD34+-hematopoietic stem and 37 
progenitor cells (HSPCs) that can differentiate into macrophages and erythroid cells.  An Mpl-based 38 
Cell Growth Switch system was shown to drive macrophage-associated erythropoiesis and the 39 
macrophages produced in this system developed a phenotype similar to EBI macrophages; they 40 
expressed EMP, ICAM-4, CD163, DNASE2 and supported the maturation of erythroid cells to 41 
orthochromatic stage (102, 103).  42 
The addition of the synthetic glucocorticoid, dexamethasone to differentiating CD34+ HPCs has been 43 
particularly useful in modelling human stress erythropoiesis in vitro (104). As erythroid 44 
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differentiation is inhibited by dexamethasone, the consequential expansion of pro-erythroblasts 1 
mimics the stressed situation. Interestingly the small population of macrophages that are generated 2 
under these conditions (3% of total culture) interact with the expanding erythroblasts to form EBIs. 3 
The presence of dexamethasone promoted the maturation of CD169+ macrophages (104), the cell 4 
phenotype that is known to promote erythropoiesis under stress conditions in murine models (66). 5 
Taken together, evidence suggests that the EBI macrophages involved in stress erythropoiesis are 6 
likely to be distinct from those in the steady state.  7 
4.2. Monocyte-derived macrophages  8 
Peripheral blood mononuclear cells (PBMCs) have been used to demonstrate that macrophages can 9 
function as a ferritin iron source for cultured human erythroblasts to synthesise hemoglobin, a long-10 
suspected role of EBI macrophages (44). In vitro modelling of the human EBI niche has been 11 
consistent with findings obtained in the murine system demonstrating that contact with 12 
macrophages promotes erythroblast proliferation. Co-culture of CD14+ PBMC-derived intermediate 13 
monocytes/macrophages with CD34+ progenitors enhanced erythropoiesis by supporting progenitor 14 
cell survival (105) and the addition of glucocorticoids induced the differentiation of monocytes to 15 
macrophages with an EBI-macrophage phenotype (106).   16 
Not only does this modelling rely on the availability of monocyte-derived macrophages, it is 17 
important to note that different effects have been reported on maturation and enucleation (63, 18 
105). Furthermore, monocyte-derived macrophages may not accurately reflect the developmental 19 
ontogeny of EBI macrophages (107-110). To improve modelling of the human EBI in vitro, 20 
macrophages were derived from induced pluripotent stem cells (iPSCs) that can provide a limitless 21 
resource. iPSC-derived macrophages can be harvested repeatedly from cultures which greatly 22 
increases the yield of available macrophages compared to monocyte-derived (109, 111). 23 
Furthermore, iPSC-derived macrophages have been demonstrated to share ontogeny with MYB-24 
independent tissue-resident macrophages, and while the exact developmental origins of EBI 25 
macrophages have not been determined, it is thought that they arise from yolk sac-derived EMPs, 26 
therefore sharing ontogeny with tissue-resident macrophages (108). 27 
4.3. iPSC-derived macrophages 28 
iPSC-derived macrophages were shown to promote the maturation and enucleation of RBCs 29 
differentiating from CD34+ hematopoietic progenitor cells in an in vitro model of the human EBI 30 
niche (8). A tamoxifen-ERT2 expression system was used whereby the transcription factor KLF1 was 31 
expressed under the control of the constitutive CAG promoter and translocated to the nucleus upon 32 
addition of tamoxifen.  Nuclear translocation and thus activation of KLF1 during the differentiation 33 
of iPSC-derived macrophages lead to the production of macrophages with an ‘EBI macrophage’ like 34 
phenotype. Macrophages expressing higher levels of KLF1 were better able to promote erythroblast 35 
maturation, resulting in an increase in enucleated RBCs in the culture (8). The use of this KLF1 36 
expression system therefore supported previous findings of an extrinsic role for KLF1 in EBI 37 
macrophages (8, 89).  38 
The use of this unique in vitro model of the human EBI enabled the identification of KLF1-regulated 39 
genes encoding secreted factor including IL-33, SERPINB2, ANGPLT7, that were shown to be 40 
important for promoting erythropoiesis (8). Addition of all three of these cytokines to differentiating 41 
CD34+ haematopoietic stem and progenitor cell cultures significantly increased the absolute number 42 
of mature, enucleated cells, with removal of individual cytokines resulting in an overall reduction in 43 
the number of mature enucleated cells. Removal of IL-33 resulted in the most significant reduction 44 
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in mature cells, but IL-33 alone did not improve maturation implying that it acts in synergy with the 1 
other factors (8). This study demonstrated that in vitro modelling of the EBI niche using iPSC-derived 2 
macrophages provides a powerful tool to identify and characterise novel factors and the key 3 
signalling and regulatory pathways involved in erythropoiesis. It will be possible to use this in vitro 4 
model in future to assess the effects of these novel factors as therapeutic options for patients with 5 
RBC disorders. For example, cytokines such as IL-33 could be investigated for their ability to promote 6 
RBC proliferation and maturation in anemic patients who do not respond to EPO treatment and 7 
small molecules to activate or block key signalling pathways could be tested as potential therapies 8 
(99, 100).   9 
The ability to genetically engineer iPSCs and thus differentiated macrophages presents a promising 10 
approach to dissect the role of individual genes within the human EBI niche (112, 113).  The wide 11 
array of genetic tools also allows for controlled temporal activation and knockout of specific genetic 12 
pathways.  The tamoxifen-ERT2 is particularly useful as it appears to recapitulate endogenous gene 13 
expression levels, avoiding very high, non-physiological expression levels often seen in standard 14 
transgenic or viral expression systems (8).  The human iPSC-derived macrophage strategy also holds 15 
great potential in the context of RBC disorders, where pathogenic gene mutations can be introduced 16 
into EBI-like macrophages, to investigate whether genetic deficiencies in niche contribute to disease 17 
pathology. 18 
In vitro modelling of the human EBI could also be used for patient-specific drug testing. This is 19 
especially useful for diseases in which animal models do not exactly recapitulate the disease. For 20 
example, the neonatal anemia, nan mouse carries a mutation (KLF1-E339D) homologous to the KLF1-21 
E325K mutation that is observed in patients with type IV congenital dyserythropoietic anemia (CDA), 22 
but the phenotype is quite different (114, 115). Macrophages and RBCs differentiated from patient-23 
derived iPSCs would allow for the in vitro modelling of EBIs in disease and could prove especially 24 
useful for dissecting the contributions of each cell type to disease pathology. Using an iPSC line 25 
derived from a CDA patient, it was shown that the KLF1-E325K mutation induces cell cycle arrest in 26 
differentiated erythroid cells (116). This was comparable to data derived from erythroid cells 27 
differentiated from patient-derived CD34+ progenitors where RNA-sequencing revealed the 28 
dysregulation of cell cycle genes (117).  In future, the production of macrophages from this patient-29 
derived iPSC line will elucidate whether the presence of the KLF1-E325K mutant protein in the EBI 30 
niche contributes to the pathology of the disease and will determine whether targeting the niche 31 
might be a therapeutic option. 32 
5. Conclusion 33 
The concept of the EBI has greatly progressed since it was first described by Bessis in 1958 with 34 
central macrophage functions, such as the role of cell-contact in promoting erythropoiesis, now well 35 
defined. In vitro models of the human and murine EBI, both intact and reconstituted, are relatively 36 
cheap and simple systems that have allowed for visual examination of the niche. Their simplicity 37 
however does not allow for dissection of the roles of individual genes, and in the human system 38 
sourcing primary tissue can be difficult (Table 1). While not possible in the human system, 39 
macrophage depletion and genetic models have been incredibly useful for understanding the role of 40 
individual genes within the mouse EBI niche. These genes are now beginning to be investigated in 41 
the human EBI niche, in which modelling using iPSC-derived macrophages now allows for the kinds 42 
of genetic manipulation employed to study the mouse system (Table 1). 43 
The advances that have been made in modelling murine and human EBIs both in vivo and in vitro 44 
have great potential to be utilised to further examine the role of the EBI niche during stress 45 
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erythropoiesis and RBC disorders, especially by elucidating molecular mechanisms that could be 1 
targeted in their treatment. To recreate the EBI niche during stress erythropoiesis it will be 2 
interesting to assess whether iPSC-derived macrophages display the characteristics of splenic RPMs 3 
and if not, to devise culture conditions or genetic strategies to mimic their phenotype.   The 4 
knowledge gained from the various models of the EBI niche could also aid in research to improve the 5 
production of functional RBCs from iPSC in vitro for clinical use. Blood transfusions, the most 6 
common treatment for RBC disorders, is reliant on donor supply and compatibility, and has side 7 
effects such as iron overload if patients require regular transfusions (118). Therefore, there is world-8 
wide interest in the development of a donor-free supply of RBCs from a renewable source such as 9 
iPSCs. While significant progress has been made in this area, the strategy has not been successful in 10 
providing a stable source of enucleated RBCs that can be scaled up for therapeutic uses (119-123). 11 
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Figure Legends 1 
Figure 1.  The role of EBI macrophages in erythropoiesis 2 
 3 
In healthy steady-state erythropoiesis, erythroblastic island macrophages support and promote 4 
erythropoiesis via membrane protein interactions, the secretion of factors, and by providing iron for 5 
heme synthesis. During terminal differentiation, EBI macrophages phagocytose nuclei extruded from 6 
differentiating erythroid cells with DNAse11 associated with its degradation. In models of stress 7 
erythropoiesis, macrophage depletion led to the phagocytosis of mature RBCs by splenic red pulp 8 
macrophages, which increased expression of SPI-C, Gdf15 and Bmp4, resulting in an increase in the 9 
proliferation of stress erythroid progenitors. Macrophage depletion led to the normalisation of RBC 10 
numbers in disease models of polycythemia vera and β-thalassemia by decreasing and increasing red 11 
blood cells, respectively. Macrophages associated with the EBI in the steady state (purple) are likely 12 
to be different from those in stress and diseased conditions (blue). 13 
 (EBI, erythroblastic island; RBC, red blood cells; RPM, red pulp macrophages; SEPs, stress erythroid 14 
progenitors). 15 
 16 
Table 1. Model systems used to study the erythroblastic island niche 17 
Summary of the different mouse and human model systems used to study the erythroblastic island 18 
niche in erythropoiesis and their advantages and disadvantages. (EBI, erythroblastic island; HSPC, 19 
hematopoietic stem/progenitor cells; iPSC, induced pluripotent stem cells) 20 
  21 
  22 
 12 
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May & Forrester (Ms. No. 20-179): Response to Reviewers 
 
Reviewer #1:  
1.Information by microscopy or even by FACS analyses of in vitro reconstituted islands are 
static and give the wrong impression that the island represents a stably associated 
structure. Macrophages, however, are very motile cells and in vitro time laps studies 
indicate that instead the island may be a dynamic structure possibly involving with time 
different cell populations. This dynamism may explain why some investigators are really 
skeptic that the island even exist.  
We had included a reference that describes the migration of EIs (ref 52) but to emphasise 
this point we have now added a sentence to make it clear that the EBI is dynamic (Page 3, 
lines 38-41). 
 
 2. The review gives the impression that the same macrophages are involved in the 
formation of the erythroblast islands in steady state and in stress erythropoiesis. This may 
not be true. The macrophage that support CD34 survival derives from monocytes 
differentiated in culture. By contrast, the macrophages generated in cultures stimulated 
with dexamethasone that promote erythroblast proliferation likely derive from the stress 
erythroid progenitor cells which are generated in response to this hormone. These 
macrophages are likely to be stress specific because are not generated in cultures which do 
not contain dexamethasone (see Falchi et al, Haematologica. 2015 Feb;100(2):178-87. This 
paper inspired refs, 102). The fact that stress macrophages derive from the stress-specific 
erythroid progenitors explain their unique dependence on KLF1.   
We have now added a separate section (Section 4.1) on CD34+ HPC-derived macrophages 
and the effect of glucocorticoids on their phenotype, citing the Falchi et al paper (ref 104) 
(Pages 7-8, lines 37-44 and 1-7).  We have added a clear statement that EBI macrophages 
involved in stress erythropoiesis are likely to be distinct from those in the steady state. 
(Page 8, lines 6-7). 
 
3.     The Figure is good and clearly summarize the main concepts of the review. I suggest to 
modify the Figure to avoid the impression that the macrophage contained in the 
erythroblastic island under steady stare and stress/disease conditions is the same, which is 
probably not true. The niche involved in stress erythropoiesis is induced by glucocorticoids. 
In addition, I would spell out some of the factors that mediate the interaction between the 
macrophages and the erythroid cells in the various niches.   
We have changed the colour of macrophages in Figure 1 to reflect the fact that 
macrophages in EI islands under steady state and stress/disease are likely to be different 
and modified the figure legend accordingly. We have added a new section on CD34+ HPC-
derived macrophages where the addition of glucocorticoids mimicked stress conditions 
and make it clear that that EBI in steady state and stress conditions are different (Pages 7-
8, lines 37-44 and 1-7). We have altered Figure 2 to include some of the specific membrane 
proteins that likely mediate the interaction between macrophages and erythroid cells 
under steady state conditions and we had added DNAseII within the macrophage which is 
involved in the degradation of the extruded nuclei (modified Figure 1).   
 
 
 
Response to Reviewers
 
Minor comments 
 
We apologise for not including page and line numbers in the original manuscript. These 
are now included and we use these in our response for ease of referral. 
 
 "completely ablates the hematopoietic system". Please change the sentence into 
"ablates the hematopoiesis of the host". After preconditioning, the resident 
macrophages in the bone marrow remain those of the host (Awaya et al Exp Hematol. 
2002 Aug;30(8):937-42. doi: 10.1016/s0301-472x(02)00821-4). 
We have altered the wording (Page 2, line 39)  
 
 "such as the fetal liver and spleen". Since the authors talk about stress erythropoiesis in 
adult animals, they probably mean "such as the liver and spleen".  
This mistake is corrected (Page 5, line 4). 
 
 How an enhanced EPO receptor signaling via JAK2 may expand macrophages in 
polycythemia vera is not immediately clear. Do we know whether the resident 
macrophages in the bone marrow derive from the PV stem cell clone? This part needs to 
be clarified.  
 We have reworded this section to hopefully clarify the fact that hyperactivity of the EpoR 
signalling within the macrophage compartment is thought to contribute to the disease 
phenotype (Page 5, lines 20-26) 
 
 The role of KLF1 in erythropoiesis should be better detailed/ made more precise. It is the 
last phase of terminal maturation (membrane-specific genes, nuclear condensation, etc) 
that is uniquely KLF1-dependent. The first part is mostly GATA1-dependent.  
We have reworded this sentence to address the reviewer’s point to “KLF1….with an 
important role in regulating the later stages of RBC production” (Page 6, line 24/25) 
 
 "Prenocytes" should be pyrenocytes, In addition, this section requires some 
modification. Pyrenocytes are not naked nuclei extruded by the cell but real cells with a 
cytoplasmic rim generated by the last asymmetric division of terminal maturation. Since 
terminal maturation destroys the cellular cytoskeleton linking the nuclear and the 
plasma membrane and the mitosis motors, the two daughter cells must rely on physical 
contacts established by the pyrenocyte with the macrophage to provide the polarity 
force necessary to trigger their separation.  
We apologise for the spelling error and have corrected this to pyrenocytes, we have added 
a description to clarify what they are and added a reference (9). (Page 6, lines18/19) 
 
 Reference 4 (Paulson of 2011) should be replaced by the most recent review published 
by Paulson in Experimental Hematology in the last few months.  
We thank the reviewer for alerting us to this reference and we have replaced ref 4 with 
this more recent review.  
 
 Reference 18 is a review on PV by Tefferi of 2003. This reference should also be replaced 
by anyone of the more recent reviews on the subject.  
We have replaced ref 18 with an updated 2019 review by the same author. 
 
 Reference 112. Whether results published by Kohara with patient-derived iPCS are 
similar to those published by Varricchio et al using patient-specific erythroblasts 
differentiated in vitro should be discussed (Haematologica. 2019 Dec;104(12):2372-
2380).  
We have now included and cited the data described by Varricchio et al and note the 
similarities in the data generated from iPSC-derived erythroid cells and the patient CD34+ 
progenitor-derived cells described in that paper (Page 9, lines 27-29). 
 
 For completeness, it is suggested to mention the contribution to the field of the Torok-
Storb laboratory (Belay E et al PLoS One. 2017 Jan 30;12(1):e0171096, Pillai et al Exp 
Hematol. 2009 Dec;37(12):1387-92 and Belay et al Blood. 2015 Feb 5;125(6):1025-33.   
We have now included and cited the work from this group (refs 102 and 103)(Page 7, lines 
37-42). This is now included as part of a separate section on the generation of EBI 
macrophages from CD34+ hematopoietic progenitor cells and we have added this as a 
separate model in Table 1.  
 
 
Reviewer #2:  
1) The concept of EBI has greatly evolved since its inception  several decades ago. Although 
the  phagocytic activity of macrophages  for processing the effete RBCs , or the pyrenocytes 
and supplying iron to the developing Erythroid cells were well accepted, other functions 
attributed to macrophages, i.e on the proliferation, on survival and terminal differentiation 
of erythroid cells were ill defined. In vitro experiments suggested contact dependent 
functions and these findings were supported by the results of antibody treatments. In vivo 
experiments addressed the dominant contribution of macrophages to stress responses, 
through Clodronate use(= a bomb with a lot of collateral damage),whereas the exact surface 
phenotype was constantly under revision. Along the way there were conflicting results, 
especially for some prior important players, i.e Spi-C ,or VCAM-1 or newer deletions of EMP 
in only erythroid cells or only in macrophages. Further, recently contact-independent 
functions of macrophages were emphasized through  several secreted proteins. The current 
review cites all the authors prior conclusions, but needs a more critical evaluation of the 
findings. 
 
We have now added text to the end of each section that includes a more critical 
evaluation of the models that are discussed (Page 4, lines 22-25; Page5, lines 33-36) and 
included a section at the start of our conclusions (Page 7, lines 22-25). 
 
2) The contribution, especially to stress erythropoiesis, of microenvironmental (ME) cells 
other than macrophages, i.e endothelial cells, perivascular cells(secretion of SCF), dendritic 
cells, or the erythroid cells themselves, is insufficiently acknowledged. Upon high Epo 
stimulation erythroid cells release several molecules (Gas 6, VEGF, PIGF, GDF11 ) with 
paracrine effects on macrophages. Epo also elicits responses from macrophages, as 
indicated recently (the presence of Epo mRNA in macrophages was first reported in 1988!). 
So macrophages participate in a well coordinated response by many other cells types. 
Please add this.  
We have added a sentence at the beginning of the macrophage depletion models in stress 
erythropoiesis section that addresses this point (Page 4 lines 34-37) 
 
3) The review is subdivided into too many subchapters; i.e Clodronate use in normal in one 
and clodronate use in PV or Thal mice in another. Also on human EBIs, the monocyte-
derived or iPSC-derived do not deserve a separate subchapter.  
As our review is focussing on the different model systems that have been used to study the 
EBI, we believe it is important to define each model in a separately titled section.  
 
Minor: 
Ref #91 is incomplete and includes a wrong composition of authors.  
Apologies, this reference is now complete 
 
Species Model Advantages Disadvantages References 
Mouse Imaging and 
isolation of intact 
EBIs 
 Visual  Static system 
 
1, 2, 50 
Mouse Reconstitution of 
islands in vitro 
 Allows the study of direct 
cell-cell interactions in a 
dynamic manner. 
 Cheap and simple 
 not possible to 
investigate possible 
interactions with other 
cell types 
 
42, 55, 57, 
58, 59, 60 
 
Mouse Macrophage 
depletion in vivo 
(eg. clodronate) 
 Easy to administer  
 Can be performed on 
different genetic models 
 Broad macrophage 
depletion 
 
63, 65 
Mouse Genetic models 
(eg lineage-specific 
knockout and 
depletion) 
 Allows for dissection of the 
role of specific cell 
populations and genes in 
vivo. 
 Costly 
 Complex 
 
56, 58, 74, 
77, 79, 80, 
81, 83, 90, 
100 
 
Human Imaging and 
isolation of intact 
EBIs 
 Visual  Static system 
 Difficult to obtain 
primary tissue 
45 
Human Reconstitution of 
EBIs in vitro using 
HSPC-derived cells. 
 Macrophage/erythroid 
interactions can be studied. 
 Relatively cheap and simple 
system 
 Macrophages and erythroid 
cells differentiate in concert 
 
 Reliant on repeated 
donations 
 Does not investigate 
involvement of other cell 
types. 
102,103,104 
Human Reconstitution of 
EBIs in vitro using 
monocyte-derived 
macrophages 
 Macrophage/erythroid 
interactions can be studied. 
 Relatively cheap and simple 
system 
 Not conducive to 
genetic manipulation 
 Reliant on repeated 
donations  
44, 105, 106 
 
Human Reconstitution of 
EBIs in vitro using 
iPSCs-derived 
macrophages 
 Macrophage/erythroid 
interactions can be studied 
 Relatively cheap and simple 
 Limitless resource 
 Genetically manipulatable  
 Disease-specific modelling 
possible 
 May not completely 
recapitulate in vivo EBIs 
8 
 
Table 1. Model systems used to study the erythroblastic island niche 
Summary of the different mouse and human model systems used to study the erythroblastic island niche in 
erythropoiesis and their advantages and disadvantages. (EBI, erythroblastic island; HSPC, hematopoietic 
stem/progenitor cells; iPSC, induced pluripotent stem cells) 
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